Uncategorized

Drug Discovery Quiz

Drug Discovery Quiz Answer. In this post you will get Quiz Answer Of Drug Discovery

 

Drug Discovery Quiz

Offered By ”University of California San Diego”

Enroll Now

Week- 1

Pharma and Biotech

 

1.
Question 1
According to the videos, in what direction is the pharmaceutical and biotechnology industry headed?

1 point

  • Efficiency.
  • Innovation and cost reduction.
  • Better and more powerful drugs.
  • Equity and Equality.

2.
Question 2

In terms of pharmaceutical developments, why has there been a shift to countries such as Asia?

1 point

  • A desire for a larger market.
  • A desire for increased STEM (Science, Technology, Engineering, and Mathematics).
  • A desire for cost reduction.
  • A desire for more employment.

3.
Question 3
Please observe the following graph:

As mentioned in the lectures, what is the main cause of the apparent rise in financial penalties in the U.S.?

1 point

  • Strengthening scientific base.
  • Tight regulations.
  • Patent Cliffs.
  • Escalating demands for medicine.

4.
Question 4

Which of the following are opportunities for the pharma market? (Choose 3)

1 point

  • Wireless Health.
  • Healthcare reduction costs.
  • Trade liberalization.
  • Strengthening Scientific base.
  • Stronger Price controls.

5.
Question 5
According to the videos, who or what determines Pharma and Biotech innovation?

1 point

  • The cost of the drug
  • The investors
  • The customers
  • The advancement of the field

6.
Question 6
According to the videos, what is the ultimate future or direction of the Pharma company?

1 point

  • Ultimate personalized medicine.
  • Biomarkers.
  • Diversity of drugs.
  • Repurposing of drugs.

7.
Question 7
What type of product distribution model leads to siloed markets?

1 point

  • Specialist model
  • Business model
  • Customer centered model
  • Blockbuster model

8.
Question 8

What are the characteristics of the blockbuster model? (Choose 2)

1 point

  • Pricing – Depends on the market
  • Pricing – Pay for performance
  • R&D – Nimble decision-making process
  • R&D – Silos

9.
Question 9
According to the videos, what is disruptive innovation in pharma?

1 point

  • Cure a disease or prevent it.
  • Improve the quality of life.
  • Superiority in comparative trials.
  • Reduce the cost of care.

10.
Question 10

Payers are not going to pay a premium unless… (Choose 2)

1 point

  • Drug shows disruptive innovation.
  • Pharma race to develop new products, which all have the same mode of action.
  • Reduce the cost of care.
  • Be better than other drugs in trials and be cost efficient.
  • Improve the quality of life.

11.
Question 11
What makes specialty drugs less costly to develop compared to most prevalent diseases?

1 point

  • Expedited reviews by the FDA and tax breaks
  • Clinical trials are smaller, only 100-200 subjects compared to several thousand
  • Seven years of competition-free marketing for new orphan drugs
  • Lower standard for scientific evidence required for orphan drugs

 

 

Week- 2

Drug Discovery: Proteomics, Genomics

 

1.
Question 1
What is the current referred issue of the omnics era when Dr.Philip used the analogy about neglecting the “long tail”?

1 point

 

Increased R&D spending but decrease in new drug approvals.

Funders are demanding data sharing plans.

DNA data is doubling every 5 months.

No one is taking care of errors, complexity, etc of the massive genome data.

2.
Question 2

Data we obtain from analyzing organisms are not only getting ___ but also getting ____.

1 point

Larger; More complex.

Complex; More unstructured.

3.
Question 3

Metagenomics is the study of genetic material recovered directly from environmental samples. What was one of the biggest challenges with metagenomics as mentioned in lecture?

1 point

Almost all data captured is completely new and rich with data.

Open sourcing data published.

We had to study human microbiomes.

Establishing a data science major.

4.
Question 4
What is open source publishing?

1 point

Giving out the source code of the code for the general public.

Making information accessible to everyone.

Acknowledgement of the author in a particular work.

5.
Question 5

What is the warning or problem with the massive amount of data growth and complexity?

1 point

The data is too complex to analyze.

Lack of proper genome sequencing methods.

Not enough data scientists.

30% of annotations in databases may be wrong.

6.
Question 6

What is our current mentality in the drug discovery process that is impeding the process?

1 point

One drug, multiple targets, multiple diseases.

Heal as many people as possible.

Maximize profit.

One drug, one target, one disease.

7.
Question 7

Why is the single silver bullet mentality bad for the drug development process?

1 point

Too risky for the company to invest in only one market.

Increases the time required to develop the drug.

Compounds often bind to more than one target.

8.
Question 8

How could computers aid in the unique processes of network pharmacology?

1 point

Calculate and aid in analysis of physiological processes.

Store massive protein data as databases to be analyzed later.

Computers cannot aid the process of network pharmacology because it cannot be as accurate as humans.

Simulate and analyze biological networks.

9.
Question 9

What is the major caution with working with systems pharmacology and computers?

1 point

Computers are too slow to deal with complexity.

There is a general mistrust with computational approaches.

Openness is an alien culture to drug discovery.

10.
Question 10
Which of the following is a major limitation of metagenomics?

1 point

Functional annotation accuracy

Scientific interest

Information technology (IT) infrastructure

Lack of data regarding function

11.
Question 11
Off-target drug screening provides information on all of the following EXCEPT:

1 point

Reason a drug failed

How to optimize a new chemical entity

Drug dose and frequency

A possible repositioning of a drug to treat a different disease

12.
Question 12
Multiscale modeling of drug actions include all of the following EXCEPT:

1 point

Understanding of dynamics and kinetics of protein-ligand interactions

Knowledge representation and discovery and model integration

Systems pharmacology

Reconstruction, analysis and simulation of biological networks

 

 

Compound Selection and Pre-clinical Studies

 

1.
Question 1

What is the success rate from research to market?

1 point

1 in 1000

1 in 10

1 in 100

2.
Question 2

Why are pharmaceutical companies placing focus (such as improvements and cost reduction) on the research and development branch?

1 point

R&D is too competitive and over inflated with non-productive workers.

Better R&D means better drugs which means improved sells.

R&D always requires large attention.

R&D takes the longest and has the highest investment in the drug development cycle.

3.
Question 3

Which is the best definition of the term First-In-Class?

1 point

 

The first product on shelves that customer will naturally get.

The first molecule designed to tackle a new problem.

A monopoly on a specific medical brand.

4.
Question 4

The videos mentioned a desire for robust efficacy in animal models for R&D requirements. What does it mean to have robust efficacy in animal models?

1 point

 

Have reproducible effect in a dose response manner: small dose => small repose, large dose=> large response.

Show a problem is able to be addressed by a specific variable threshold.

Joint ownership and responsibility of the animal tests.

5.
Question 5

When a medicine is designed for oral intake use, would the testing process test the medicine in non-oral intake ways?

1 point

 

Yes

No

6.
Question 6

What is the Ames Assay?

1 point

 

Another name for tier 3 of the research testing.

A type of report required for the composition of the chemical compound.

A type of test within the assay flow to detect the genetic toxicity of the compound.

7.
Question 7

Which is the best description of what X-Ray crystallography does?

1 point

 

Determines the genetic toxicity of a compound.

Determines the half life of the compound.

Finds the structure of the compound.

8.
Question 8

Of the following questions, which best represents the problem that Pharmacokinetic is trying to tackle?

1 point

 

What is going on in the body when the compound enters into it?

How does the oxidative process work on the compound?

How will your drug interact with other drugs on the market?

How does the drug affect the DNA?

9.
Question 9
Which of the following statements is true? (Select 2)

1 point

Small molecule drug candidates should activate both hERG and CYP450 proteins

One of the FDA requirements for small molecule drug candidates is to not inhibit hERG channel.

Small molecule drug candidates should not inhibit the cytochrome CYP450

10.
Question 10
What is SPR (surface plasmon resonance)?

1 point

A method to measure the change in fluorescence of a protein upon a small molecule binding,

A method to measure the effect of temperature on protein stability.

A label-free method which is used to characterize the kinetics of protein-ligand interactions. It provides the values for Kd, Ka, stoichiometry and kon/koff parameters.

11.
Question 11
Which of the following is considered a third tier study?

1 point

Receptor binding study

Ames mutagenicity study

Dose escalation pharmacokinetic study

Animal model protein binding study

12.
Question 12
Which of the following is an inappropriate criteria for drug discovery?

1 point

Unknown efficacy in rodent automimmune disease models

Suitable for oral, once daily dosing

Target selectivity

Structurally unique molecule

13.
Question 13
All of the following are common in vivo models for pharmacokinetic/pharmacodynamic profiling EXCEPT:

1 point

Cynomolgus monkeys

Sprague-Dawley rats

Beagle dogs

Bobtail Cats

14.
Question 14
Which of the following are typical compound criteria in research?

1 point

Structurally unique molecule

Target selectivity >1,000 fold selective vs. closely related target

Focus on First-in-Class or Best-in-Class

Efficacy in relevant animal models

15.
Question 15
Which of the following is used as an antitarget to evaluate potential cardiotoxicity?

1 point

hERG

HepG2 cytotoxicity panel

Ames mutagenicity test

Human 5 major P450s

16.
Question 16
Which of the following parameters are typical in pharmakokinetics and pharmakodynamics?

1 point

Half-life in blood

Interaction with other drugs

Induction of cytochrome P450s

Inhibition of cytochrome P450s

17.
Question 17
Which of the following preclinical tests and animal methods were used in testing a compound for treatment of diabetes?

1 point

Different mouse strains

Non-Obese/Diabetic rats

Immunehistochemical staining of insuline in microscopic sections of Langerhans’ islets in the pancreas

Monkeys

 

 

Week- 3

Challenges in Fragment Based Drug Discovery for Protein Kinases

 

1.
Question 1
All of the following are suitable target directed screening methods EXCEPT:

1 point

Stem cells

Gene family platforms

Diversity/iterative screening (HTS)

Compound libraries

2.
Question 2
All of the following are perceived or real challenges to fragment-based drug discovery EXCEPT:

1 point

Modest fragment libraries

Lipophilicity of a drug

Drug Size

Lack of advanced cellular assays

3.
Question 3
All of the following are suitable for an oral drug candidate EXCEPT:

1 point

Lipophilic ligand efficiency (LLE) greater than 5

Partition coefficient log P (cLogp) less than 3

LEAN less than 0.27

Molecular weight (MW) less than 400

4.
Question 4
cLogP is a measure of compound lipophilicity. What compound property does P represent?

1 point

Pressure

Partition coefficient

Probability of binding

Permeability

5.
Question 5
Which of the following is the right value for a compound to be suitable drug candidate?

1 point

cLogP > 0.27

cLogP > 5

cLogP < 5

cLogP < 3

6.
Question 6
The equation

LLE =-log(IC50) – cLogP

describes the relationship between the value of Lipophilic Ligand Efficiency (LLE) and some compound properties.

What does IC50 represent?

1 point

The compound concentration required to kill 50% of tested animal population

 

The compound concentration which activates 50% of target in vitro

 

The compound concentration which inhibits 50% of target in vitro

7.
Question 7
All of the following are correct statements EXCEPT which one?

1 point

Pharmacokinetics and drug metabolism is a significant attrition parameter in drug discovery and development

The presence of chiral centres in a compound makes it a bad drug candidate

Economic and cost-related factors are contributing to about 1/3 of problems in drug development

Clinical safety is an attrition factor for drug discovery and development.

8.
Question 8
Compound efficacy contributes for about 1/3 of the failed cases in small molecule drug discovery. Which of the following statements defines the meaning of Efficacy?

1 point

Compound binds strongly on the protein target

Compound binds on the protein target, blocks its function in the body but does not have the expected therapeutic/treating effect.

Compound binds on its target and results in the treatment/cure of the pathological condition and delivers the expected therapeutic results

9.
Question 9
All EXCEPT one are correct statements. Please identify the wrong statement.

Medicinal chemists are facing the following challenges when they synthesise compounds that are candidates for drug discovery:

1 point

Compounds should have chiral centres and a good balance between Nitrogen and Oxygen

 

Compounds should be colored

Compounds should have MW smaller than 400

Compounds should have ideally low lipophilicity

10.
Question 10
What is the main goal of the Fragment Based Drug Discovery approach?

1 point

To go from small heterocyclic fragments with weak/medium binding affinity to a compound with MW below 400, tight binding (IC50<10nM) and specific/selective binding.

To identify planar compounds which bind to more than one closely-related targets

To create a large library of compounds with MW<500

 

 

Concepts in Drug Delivery Quiz

 

1.
Question 1
Which of the following poses a challenge to the oral absorption of drugs?

1 point

Drug Solubility

Drug Permeability

All stated responses are correct

Gut and 1st Pass (liver) enzyme stability

2.
Question 2
Which of the following is a physiologic factor that influences the oral absorption of a drug?

1 point

Kidney function

Respiratory function

Protein binding

Gastric emptying rate

3.
Question 3
Which of the following is a disadvantage of nasel systemic delivery?

1 point

Rapid absorption

Avoidance of 1st pass loss

Irritation, inflammation or toxicity

Large surface area

4.
Question 4
ADME refers to what?

1 point

absorption distribution metabolism excretion

absorption dilution metabolism execution

5.
Question 5
What is “kinetics” referring to in “pharmacokinetics”?

1 point

how fast the drugs travel through the body

the effects of the drugs on the body

the concentration of the drugs in the body

6.
Question 6
Which three of the following are challenges to oral absorption? (select 3)

1 point

varying ph levels trough outs the GI tract

varying temperatures throughout the GI tract

drugs must stay stable when getting through the liver

drugs have to navigate in all the environments of your GI tract

 

 

 

 

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *